MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning announced that it has been approved for listing on the Nasdaq Capital Market.

Trading of the company on the big board is expected to begin on April 27, with the company to be listed under the symbol “MNMD”. The company is expected to continue to be listed on the Neo Exchange in Canada as well, with its symbol remaining unchanged.

Commenting on the achievement, CEO JR Rahn stated, “We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

MindMed last traded at $2.67 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Red Cloud Fall Mining Showcase 2026 | Day 1

Can an Old Irish Mine Recover the Silver It Left Behind? | Julian Vickers – Northmin Corporation

Is Gold at $4,000 a Buy Zone or a Breakdown? | David Morgan

Recommended

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Meghan Markle’s Half-Brother Submitted Evidence Against Their Father, But Now Faces Philippine Police Scrutiny

Related News

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

Mind Medicine CFO Quits Ahead Of Release Of 2021 Financial Results

It’s always a positive sign when a chief financial officer resigns the last business day...

Monday, March 28, 2022, 06:45:00 AM

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results....

Tuesday, November 17, 2020, 10:17:00 AM

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for...

Wednesday, May 26, 2021, 10:14:37 AM